CFDE Workbench
InfoDataCloudKnowledgetrainingcoordination
Search
Graph
Enrichment
Cross
Assistant
Data Matrix
Use Cases
Tools & Workflows
Submit
Documentation
CFDE Workbench

PIK3C2G (Gene)

Organism:

Homo sapiens

Taxonomy (Entity type)
Synonyms:ENTREZ:5288, HGNC:8973, MIM:609001, NM_001288772, NM_001288774, NM_004570, NP_001275701, NP_001275703, NP_004561, PI3K-C2-gamma, PI3K-C2GAMMA, PIK3C2G, XM_011520696, XM_011520697, XM_011520700, XM_011520701, XM_017019470, XM_017019471, XM_017019472, XM_017019473, XM_017019474, XM_017019475, XM_017019476, XM_017019477, XM_017019478, XM_017019479, XP_011518998, XP_011518999, XP_011519002, XP_011519003, XP_016874959, XP_016874960, XP_016874961, XP_016874962, XP_016874963, XP_016874964, XP_016874965, XP_016874966, XP_016874967, XP_016874968, XR_931307, phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma
Omim:OMIM:609001
Nci:C102945
Id:ENSG00000139144
Hgnc:HGNC:8973
Entrez:5288
Ensembl:ENSG00000139144
Description:phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma
The protein encoded by this gene belongs to the phosphoinositide 3-kinase (PI3K) family. PI3-kinases play roles in signaling pathways involved in cell proliferation, oncogenic transformation, cell survival, cell migration, and intracellular protein trafficking. This protein contains a lipid kinase catalytic domain as well as a C-terminal C2 domain, a characteristic of class II PI3-kinases. C2 domains act as calcium-dependent phospholipid binding motifs that mediate translocation of proteins to membranes, and may also mediate protein-protein interactions. This gene may play a role in several diseases, including type II diabetes. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2014]

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View PIK3C2G's neighborhood in the knowledge graph.

Submit
Playbook Workflow Builder
Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with PIK3C2G.

Gene Partnership Appyter
CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using PIK3C2G.

Submit
Gene and Drug Landing Page Aggregator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for PIK3C2G.

Submit
Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with PIK3C2G.

Results found

Linked to

 

Label

Description

 

Gene Set

GSE202434 GSE202438 talazoparib 4 v 14 human dn

Gene Set (Entity type)

A Gene Set from LINCS

Gene Set

GSE206927 PPARG knockdown endothelial cell 1 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

Gene Set

GSE183041 cisplatin 1 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

Gene Set

GSE214335 SOX9 knockout Huh-7 1 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

Gene Set

GSE183041 1 V 0 CISPLATIN HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

Gene Set

GSE149768 hypoxanthine 3 v 4 human dn

Gene Set (Entity type)

A Gene Set from LINCS

Gene Set

GSE225901 dexamethasone 2 v 3 human up

Gene Set (Entity type)

A Gene Set from LINCS

Gene Set

GSE207376 GSE207377 nutlin-3 0 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

Gene Set

GSE216043 11 V 6 CISPLATIN HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

Gene Set

GSE216043 cisplatin 3 v 6 human up

Gene Set (Entity type)

A Gene Set from LINCS

  • Gene Set

    GSE202434 GSE202438 talazoparib 4 v 14 human dn

    Gene Set (Entity type)

    A Gene Set from LINCS

  • Gene Set

    GSE206927 PPARG knockdown endothelial cell 1 v 0 human dn

    Gene Set (Entity type)

    A Gene Set from LINCS

  • Gene Set

    GSE183041 cisplatin 1 v 0 human dn

    Gene Set (Entity type)

    A Gene Set from LINCS

  • Gene Set

    GSE214335 SOX9 knockout Huh-7 1 v 0 human dn

    Gene Set (Entity type)

    A Gene Set from LINCS

  • Gene Set

    GSE183041 1 V 0 CISPLATIN HUMAN DN

    Gene Set (Entity type)

    A Gene Set from LINCS

  • Gene Set

    GSE149768 hypoxanthine 3 v 4 human dn

    Gene Set (Entity type)

    A Gene Set from LINCS

  • Gene Set

    GSE225901 dexamethasone 2 v 3 human up

    Gene Set (Entity type)

    A Gene Set from LINCS

  • Gene Set

    GSE207376 GSE207377 nutlin-3 0 v 2 human dn

    Gene Set (Entity type)

    A Gene Set from LINCS

  • Gene Set

    GSE216043 11 V 6 CISPLATIN HUMAN UP

    Gene Set (Entity type)

    A Gene Set from LINCS

  • Gene Set

    GSE216043 cisplatin 3 v 6 human up

    Gene Set (Entity type)

    A Gene Set from LINCS

    • DISPLAY PER PAGE
    CFDE Workbench
    Report a bug
    Consortium
    About the CFDECF ProgramsCFDE CentersPartnershipsPilot Projects
    Community
    Workbench TutorialTraining & OutreachDocumentationGet QR CodesFunding Opportunities
    Resources
    Data & MetadataToolsChatbotUse CasesPublications
    @CFDE Workbench 2026
    The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.
    Consortium
    About the CFDECF ProgramsCFDE CentersPartnershipsPilot Projects
    Community
    Workbench TutorialTraining & OutreachDocumentationGet QR CodesFunding Opportunities
    Resources
    Data & MetadataToolsChatbotUse CasesPublications
    CFDE Workbench
    Report a bug
    The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.
    @CFDE Workbench 2026
    This repository is under review for potential modification in compliance with Administration directives.